NLRP3 and asthma: found that Oridonin treatment significantly reduced the expression of IL-4-induced cleaved caspase-1, ASC, and NLRP3 proteins in an in vitro pediatric asthma model, suggesting its potential as a novel therapeutic agent for NLRP3-mediated allergic asthma (144).